Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 2Vaping 1Uterine Cervical Dysplasia 1Smoking Cessation 1Pain 1Nevus, Spindle Cell 1Nevus, Pigmented 1Nevus, Epithelioid and Spindle Cell 1Nevus, Blue 1Nevus 1Nevi and Melanomas 1Neoplasms 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Dysplastic Nevus Syndrome 1Cutaneous Squamous Cell Carcinoma 1Breast Neoplasms 1Agnosia 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 99Fluorouracil 90Capecitabine 86Radiotherapy 81Dexamethasone 81Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Drug Therapy 65Leucovorin 64Cetuximab 60Erlotinib Hydrochloride 56atezolizumab 53Sorafenib 53Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Transdermal Patch × Clear all
NCT00644787 2013-06-13

A Dose-Finding Study of Fentanyl (JNS020 QD) 1-Day Transdermal Patch in Participants With Cancer Pain

Janssen Pharmaceutical K.K.

Phase 2/3 Completed
156 enrolled 14 charts

Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡